【摘要】 目的对比分析Ozurdex与康柏西普治疗视网膜静脉阻塞继发黄斑水肿(RVO-ME)的临床疗效。方法选取2018年2月至2020年5月就诊于我院,并经荧光素眼底血管造影(FFA)、光学相干断层扫描(OCT)检查确诊的RVO-ME患者44例44眼,22例患者选择Ozurdex治疗(Ozurdex组),22例患者选择康柏西普治疗(康柏西普组),所有患者均进行玻璃体内注药。对比并分析两组患者治疗前和治疗后1个月、2个月、3个月、4个月、6个月、12个月的最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT)、眼压、眼前段及眼底情况等变化,以及可能出现的并发症。结果 Ozurdex组和康柏西普组患者治疗后1个月、2个月、3个月、4个月、6个月、12个月的BCVA及CMT与治疗前相比,差异均有统计学意义(均为P<0.05)。Ozurdex组和康柏西普组治疗后不同时间点BCVA及CMT比较,差异均无统计学意义(均为P>0.05)。Ozurdex组患者玻璃体内注射次数为(2.09±0.68)次,康柏西普组为(5.14±1.21)次,差异有统计学意义(P<0.05)。两组患者治疗后不同时间点眼压与治疗前比较,差异均无统计学意义(均为P>0.05);两组患者术后均未发生眼内炎、视网膜脱离等不良反应。结论 Ozurdex和康柏西普玻璃体内注射均可有效改善RVO-ME患者视功能及降低CMT,但Ozurdex疗效持续时间较长,注射次数较少。更多还原

【Abstract】 Objective To explore the comparison of clinical efficacy of Ozurdex and Conbercept in the treatment of macular edema secondary to retinal vein occlusion(RVO-ME).Methods A total of 44 patients with 44 eyes of RVO-ME who were diagnosed by fundus fluorescein angiography(FFA) and optical coherence tomography(OCT) from February 2018 to May 2020 were selected for treatment in our hospital, of whom 22 patients chose Ozurdex treatment(Ozurdex group), and 22 patients chose conbercept treatment(conbercept group), and all patients received intravitreal injection. The changes of best corrected visual acuity(BCVA), macular fovea retinal thickness(CMT), ocular pressure, anterior segment and fundus conditions, as well as possible complications, were compared and analyzed before treatment and 1 month, 2 months, 3 months, 4 months, 6 months and 12 months after treatment.Results Compared with those before treatment, the differences in BCVA and CMT of patients in the Ozurdex group and the conbercept group were statistically significant at 1 month, 2 months, 3 months, 4 months, 6 months, and 12 months after treatment(all P<0.05). There was no statistically significant difference in BCVA and CMT between the Ozurdex group and the conbercept group at different time points after treatment(all P>0.05). The number of intravitreal injections in the Ozurdex group was(2.09±0.68) times, and the number of intravitreal injections in the conbercept group was(5.14±1.21) times, and the difference was statistically significant(P<0.05). There was no significant difference in intraocular pressure between the two groups of patients at different time points after treatment and before treatment(all P>0.05). There were no adverse reactions such as endophthalmitis and retinal detachment in the two groups.Conclusion Both Ozurdex and conbercept intravitreal injection can effectively improve the visual function and reduce CMT in patients with RVO-ME, but Ozurdex has a longer duration of efficacy and fewer injections.更多还原